Tempus AI, Inc. (TEM) Stock Price: $49.59+0.11 (+0.22%)
At close: Jun 11, 2026, 4:00 PM ET
The closing share price for Tempus AI, Inc. (TEM) stock was $49.59 for Thursday, June 11, 2026, up 0.22% on the day.
Longer view (total return, dividends reinvested): past 12 months -29.9%
TEM Price Chart
TEM Key Metrics
See All MetricsTEM Earnings Preview
Next Earnings Date
Aug 14, 2026
63 days away
EPS Estimate
-0.13
Revenue Est.
$380.26M
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.20
Revenue
$348.12M
vs Estimate
$345.44M
TEM Analyst Ratings
Consensus Rating
Based on 15 analysts
Average Price Target
$66.53
+34.2% upside
Low
$35.00
Current
$49.59
High
$100.00
TEM Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $-0.12 | $-0.11 | $-0.11 | 3 |
| Q2 2027 | $-0.09 | $-0.08 | $-0.08 | 5 |
| Q3 2027 | $-0.03 | $-0.03 | $-0.03 | 3 |
| Q4 2027 | $0.02 | $0.03 | $0.03 | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-0.64 | $-0.08 | $0.60 | 10 |
| FY 2028 | $-0.10 | $0.66 | $1.22 | 8 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $428.91M | $433.73M | $442.24M | 5 |
| Q2 2027 | $460.36M | $465.52M | $474.66M | 6 |
| Q3 2027 | $493.73M | $499.27M | $509.06M | 9 |
| Q4 2027 | $532.58M | $538.56M | $549.12M | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $1.87B | $1.95B | $2.02B | 13 |
| FY 2028 | $2.31B | $2.31B | $2.32B | 10 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
TEM Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1TEM | $8.65B | $49.59 | +0.22% | -29.95% | N/A | N/A |
TEM Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky